Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis - PubMed (original) (raw)
. 2003 Nov 1;63(21):7462-7.
Affiliations
- PMID: 14612546
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis
Sabine Wintterle et al. Cancer Res. 2003.
Abstract
Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities. B7-homologue 1 (B7-H1), a recently identified homologue of B7.1/2 (CD80/86), has been described to exert costimulatory and immune regulatory functions. We investigated the expression and the functional activity of B7-H1 in human glioma cells in vitro and in vivo. Although lacking B7.1/2 (CD80/86), all 12 glioma cell lines constitutively expressed B7-H1 mRNA and protein. Exposure to IFN-gamma strongly enhanced B7-H1 expression. Immunohistochemical analysis of malignant glioma specimens revealed strong B7-H1 expression in all 10 samples examined, whereas no B7-H1 expression could be detected on normal brain tissues. To elucidate the functional significance of glioma cell-related B7-H1 expression, we performed coculture experiments of glioma cells with alloreactive CD4+ and CD8+ T cells. Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1). B7-H1 expression may thus significantly influence the outcome of T-cell tumor cell interactions and represents a novel mechanism by which glioma cells evade immune recognition and destruction.
Similar articles
- Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Schreiner B, et al. J Neuroimmunol. 2004 Oct;155(1-2):172-82. doi: 10.1016/j.jneuroim.2004.06.013. J Neuroimmunol. 2004. PMID: 15342209 - Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies.
Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmüller H, Melms A, Weller M. Wiendl H, et al. FASEB J. 2003 Oct;17(13):1892-4. doi: 10.1096/fj.03-0039fje. Epub 2003 Aug 15. FASEB J. 2003. PMID: 12923066 - The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans.
Salih HR, Wintterle S, Krusch M, Kroner A, Huang YH, Chen L, Wiendl H. Salih HR, et al. Exp Hematol. 2006 Jul;34(7):888-94. doi: 10.1016/j.exphem.2006.03.006. Exp Hematol. 2006. PMID: 16797416 - Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis.
Cao Y, Zhang L, Ritprajak P, Tsushima F, Youngnak-Piboonratanakit P, Kamimura Y, Hashiguchi M, Azuma M. Cao Y, et al. Cancer Res. 2011 Jul 15;71(14):4737-41. doi: 10.1158/0008-5472.CAN-11-0527. Epub 2011 Jul 5. Cancer Res. 2011. PMID: 21730022 Review. - Significance of B7-H1 overexpression in kidney cancer.
Thompson RH, Kwon ED. Thompson RH, et al. Clin Genitourin Cancer. 2006 Dec;5(3):206-11. doi: 10.3816/CGC.2006.n.038. Clin Genitourin Cancer. 2006. PMID: 17239274 Review.
Cited by
- Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis.
Lv K, Du X, Chen C, Yu Y. Lv K, et al. Front Oncol. 2024 Aug 7;14:1361530. doi: 10.3389/fonc.2024.1361530. eCollection 2024. Front Oncol. 2024. PMID: 39175478 Free PMC article. - Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.
Lee-Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga RA, Jusué-Torres I, Xiao T, Arrieta VA, Zhang DY, Lopez-Rosas A, Han Y, Sonabend AM, Horbinski CM, Stupp R, Balyasnikova IV, Lesniak MS. Lee-Chang C, et al. J Exp Med. 2021 Jan 4;218(1):e20200913. doi: 10.1084/jem.20200913. J Exp Med. 2021. PMID: 32991668 Free PMC article. - Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects.
Wang X, Lu J, Guo G, Yu J. Wang X, et al. Cell Death Dis. 2021 Mar 19;12(4):299. doi: 10.1038/s41419-021-03568-0. Cell Death Dis. 2021. PMID: 33741903 Free PMC article. Review. - Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Gedeon PC, et al. Expert Rev Clin Pharmacol. 2020 Oct;13(10):1147-1158. doi: 10.1080/17512433.2020.1817737. Epub 2020 Sep 11. Expert Rev Clin Pharmacol. 2020. PMID: 32862726 Free PMC article. - Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
He YF, Wang XH, Zhang GM, Chen HT, Zhang H, Feng ZH. He YF, et al. Cancer Immunol Immunother. 2005 Sep;54(9):891-7. doi: 10.1007/s00262-004-0654-1. Epub 2005 Mar 18. Cancer Immunol Immunother. 2005. PMID: 15776283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials